ANGN - Angion Biomedica Corp.
After hours:
| Previous close | 1.0000 |
| Open | 1.0600 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 1200 |
| Day's range | 1.0000 - 1.0000 |
| 52-week range | 1.0000 - 20.4000 |
| Volume | |
| Avg. volume | 8,889 |
| Market cap | 30.114M |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Zacks
Angion (ANGN) Down on Merger Agreement With Private Biotech
Angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.
- Simply Wall St.
Bullish insiders bet US$857k on Angion Biomedica Corp. (NASDAQ:ANGN)
Multiple insiders secured a larger position in Angion Biomedica Corp. ( NASDAQ:ANGN ) shares over the last 12 months...
- Zacks
Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review
The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.
- Zacks
BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing
The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox.
- Zacks
Imago (IMGO) Shares Surge 104% on Buyout Offer From Merck
Imago BioSciences (IMGO) to be acquired by pharma-giant Merck (MRK) for $1.35 billion. The transaction is likely to close by first-quarter 2023.
- Zacks
Apellis (APLS) Rises on FDA Acceptance of NDA Amendment for GA
The FDA accepts Apellis' (APLS) major amendment to the NDA for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration. A decision is now due on Feb 26, 2023. Stock up.
- Zacks
Ardelyx (ARDX) Up 41% After FDA Committee Endorses CKD Drug
The FDA's CRDAC recommends granting marketing approval to Ardelyx's (ARDX) oral pill to control serum phosphorus in adult patients with chronic kidney disease on dialysis.
- Zacks
4D Molecular (FDMT) Stock Up 178% in One Month: Here's Why
4D Molecular's (FDMT) progress with the development of its pipeline candidates in cystic fibrosis and wet AMD indications have been significant catalysts for the stock.
- Zacks
Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down
Due to discontinuing the development of its lead candidate, Neoleukin (NLTX) has no pipeline candidates in clinical development. Management undertakes restructuring initiatives to curb cash burn.
- Simply Wall St.
Angion Biomedica Third Quarter 2022 Earnings: US$0.30 loss per share (vs US$0.53 loss in 3Q 2021)
Angion Biomedica ( NASDAQ:ANGN ) Third Quarter 2022 Results Key Financial Results Net loss: US$8.99m (loss narrowed by...
- Zacks
Jazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive Sales
Jazz's Q3 earnings and sales beat expectations on strong demand for new drugs and drugs added with the GW Pharmaceuticals acquisition. The company raises the mid-point of its 2022 sales guidance.
- Zacks
Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '22 EPS View
Perrigo (PRGO) reports dismal third-quarter 2022 results. Unfavorable currency movements force management to lower earnings outlook for 2022. Shares down.
- Zacks
Karuna Therapeutics (KRTX) Posts Wider-Than-Expected Q3 Loss
Karuna Therapeutics (KRTX) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales.
- Zacks
Moderna's (MRNA) Lags on Q3 Earnings, Lowers '22 Sales Outlook
Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales.
- Zacks
Sarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag Estimates
Sarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales. Shares decline in after-market trading post the announcement.
- Zacks
Allogene (ALLO) Reports Narrower-Than-Expected Loss in Q3
Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the mark. ALLO will host an R&D showcase later this month and discuss updated clinical data on its pipeline candidates.
- Zacks
Esperion (ESPR) Q3 Earnings Beat Estimates, Revenues Miss
Esperion Therapeutics (ESPR) reports mixed third-quarter results, beating earnings estimates but missing out on sales.
- Zacks
Lilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 View
Eli Lilly's (LLY) earnings and sales surpass third-quarter estimates. The company lowers 2022 financial view for the third time this year. The stock falls in pre-market trading.
- Zacks
Best Momentum Stocks to Buy for October 25th
PHX, ARRY and ANGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 25, 2022.
- Simply Wall St.
Is Angion Biomedica (NASDAQ:ANGN) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
